Manuel José Justiniano, Giselle Marisa Rodríguez, Maria Silvia Passerini
{"title":"Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population.","authors":"Manuel José Justiniano, Giselle Marisa Rodríguez, Maria Silvia Passerini","doi":"10.5005/jp-journals-10078-1452","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim and background: </strong>To assess the efficacy of 2% dorzolamide/0.5% timolol/0.2% brimonidine tartrate fixed combination (DTB-FC) eye drops in patients with intermediate glaucoma stage.</p><p><strong>Materials and methods: </strong>A retrospective case series study was performed, including eyes diagnosed with primary open-angle (POAG) or chronic angle-closure glaucoma (CACG), which were at intermediate stage of the illness according to the Brusini grading system and were initially treated with 2% dorzolamide/0.5% timolol fixed combination (DT-FC), and switched at baseline to DTB-FC. Main outcome was intraocular pressure (IOP) baseline measured, as well as at weeks 1 and 2, months 1, 3, and 6, and 1 year after switching. IOP differences were analyzed using analysis of variance (ANOVA) repeated measures.</p><p><strong>Results: </strong>A total of 36 eyes from 22 patients were included in the study. The median age of the participants was 61 years [interquartile range (IQR) 53-71], with 59.1% (<i>n</i> = 13) being female. At baseline, 1, 2 weeks, 1, 3, 6 months, and 1 year after switching to DTB-FC, the mean IOP values were 20.3 (95% CI, 19.5-21.1), 15.3 (95% CI, 14.5-16.1), 15.5 (95% CI, 14.7-16.2), 15.5 (95% CI, 14.8-16.0), 15.5 (95% CI, 14.9-16.2), 15.5 (95% CI, 14.8-16.2) and 15.3 (95% CI, 14.7-15.9) mm Hg, respectively (<i>p</i> > 0.001). The mean IOP reduction after 1 year of treatment was -5.0 ± (4.2-5.8) mm Hg. Treatment success rates were 86.1, 80.6, 80.6, 77.8, 72.2, and 66.7%, respectively. When stratified by diagnosis, there were no statistically significant differences in the treatment success rates between POAG and CACG (<i>p</i> > 0.05).</p><p><strong>Conclusion: </strong>Therapy switching from DT-FC to DTB-FC was shown to be effective in reducing IOP of eyes with POAG or CACG during 6-12 months.</p><p><strong>Clinical significance: </strong>The DTB-FC therapy improved the therapeutic management of POAG or CACG previously treated with DT-FC therapy, which may be relevant to prevent its progression in the future.</p><p><strong>How to cite this article: </strong>Justiniano JM, Rodríguez GM, Passerini MS. Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. J Curr Glaucoma Pract 2024;18(4):137-141.</p>","PeriodicalId":15419,"journal":{"name":"Journal of Current Glaucoma Practice","volume":"18 4","pages":"137-141"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915360/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Current Glaucoma Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10078-1452","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Aim and background: To assess the efficacy of 2% dorzolamide/0.5% timolol/0.2% brimonidine tartrate fixed combination (DTB-FC) eye drops in patients with intermediate glaucoma stage.
Materials and methods: A retrospective case series study was performed, including eyes diagnosed with primary open-angle (POAG) or chronic angle-closure glaucoma (CACG), which were at intermediate stage of the illness according to the Brusini grading system and were initially treated with 2% dorzolamide/0.5% timolol fixed combination (DT-FC), and switched at baseline to DTB-FC. Main outcome was intraocular pressure (IOP) baseline measured, as well as at weeks 1 and 2, months 1, 3, and 6, and 1 year after switching. IOP differences were analyzed using analysis of variance (ANOVA) repeated measures.
Results: A total of 36 eyes from 22 patients were included in the study. The median age of the participants was 61 years [interquartile range (IQR) 53-71], with 59.1% (n = 13) being female. At baseline, 1, 2 weeks, 1, 3, 6 months, and 1 year after switching to DTB-FC, the mean IOP values were 20.3 (95% CI, 19.5-21.1), 15.3 (95% CI, 14.5-16.1), 15.5 (95% CI, 14.7-16.2), 15.5 (95% CI, 14.8-16.0), 15.5 (95% CI, 14.9-16.2), 15.5 (95% CI, 14.8-16.2) and 15.3 (95% CI, 14.7-15.9) mm Hg, respectively (p > 0.001). The mean IOP reduction after 1 year of treatment was -5.0 ± (4.2-5.8) mm Hg. Treatment success rates were 86.1, 80.6, 80.6, 77.8, 72.2, and 66.7%, respectively. When stratified by diagnosis, there were no statistically significant differences in the treatment success rates between POAG and CACG (p > 0.05).
Conclusion: Therapy switching from DT-FC to DTB-FC was shown to be effective in reducing IOP of eyes with POAG or CACG during 6-12 months.
Clinical significance: The DTB-FC therapy improved the therapeutic management of POAG or CACG previously treated with DT-FC therapy, which may be relevant to prevent its progression in the future.
How to cite this article: Justiniano JM, Rodríguez GM, Passerini MS. Triple-fixed Combination of Dorzolamide/Timolol/Brimonidine: Efficacy Study in Bolivian Population. J Curr Glaucoma Pract 2024;18(4):137-141.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
